| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial FE Silverstein, G Faich, JL Goldstein, LS Simon, T Pincus, A Whelton, ... Jama 284 (10), 1247-1255, 2000 | 4526 | 2000 |
| Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial JF Colombel, WJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, ... Gastroenterology 132 (1), 52-65, 2007 | 2796 | 2007 |
| Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial WJ Sandborn, SB Hanauer, P Rutgeerts, RN Fedorak, M Lukas, ... Gut 56 (9), 1232-1239, 2007 | 1317 | 2007 |
| Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial WJ Sandborn, P Rutgeerts, R Enns, SB Hanauer, JF Colombel, ... Annals of internal medicine 146 (12), 829-838, 2007 | 1278 | 2007 |
| Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis MH Schiff, GR Burmester, JD Kent, AL Pangan, H Kupper, SB Fitzpatrick, ... Annals of the rheumatic diseases 65 (7), 889-894, 2006 | 488 | 2006 |
| Adalimumab for the treatment of fistulas in patients with Crohn’s disease JF Colombel, DA Schwartz, WJ Sandborn, MA Kamm, G D’Haens, ... Gut 58 (7), 940-948, 2009 | 487 | 2009 |
| Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study WJ Sandborn, WF Stenson, J Brynskov, RG Lorenz, GM Steidle, ... Clinical Gastroenterology and Hepatology 4 (2), 203-211, 2006 | 289 | 2006 |
| The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status AT Lee, W Li, A Liew, C Bombardier, M Weisman, EM Massarotti, J Kent, ... Genes & Immunity 6 (2), 129-133, 2005 | 264 | 2005 |
| Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis H Kupper, JD Kent, MA Cifaldi, JL Perez, GR Burmester, P Mease, ... US Patent 9,399,061, 2016 | 215 | 2016 |
| The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior … S Lichtiger, DG Binion, DC Wolf, DH Present, AG Bensimon, E Wu, AP Yu, ... Alimentary pharmacology & therapeutics 32 (10), 1228-1239, 2010 | 211 | 2010 |
| Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors WB White, J Kent, A Taylor, KM Verburg, JB Lefkowith, A Whelton Hypertension 39 (4), 929-934, 2002 | 208 | 2002 |
| Uses and compositions for treatment of rheumatoid arthritis JR Medich, H Kupper, JD Kent, JL Perez, EH Sasso, O Segurado, ... US Patent App. 11/800,531, 2008 | 191 | 2008 |
| Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis DH Sikes, NM Agrawal, WW Zhao, JD Kent, DP Recker, KM Verburg European journal of gastroenterology & hepatology 14 (10), 1101-1111, 2002 | 159 | 2002 |
| The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations SM Smith, RH Dworkin, DC Turk, R Baron, M Polydefkis, I Tracey, ... The Journal of Pain 18 (7), 757-777, 2017 | 154 | 2017 |
| Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites J Clària, JD Kent, M López‐Parra, G Escolar, L Ruiz‐del‐Arbol, P Ginès, ... Hepatology 41 (3), 579-587, 2005 | 110 | 2005 |
| Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM S Schreiber, W Reinisch, JF Colombel, WJ Sandborn, DW Hommes, J Li, ... Gastroenterology 132 (4), A147-A147, 2007 | 100 | 2007 |
| Uses and compositions for treatment of rheumatoid arthritis JR Medich, H Kupper, JL Perez, JD Kent, EH Sasso, O Segurado, ... US Patent App. 13/280,613, 2012 | 88 | 2012 |
| Valdecoxib does not impair platelet function PT Leese, S Talwalker, JD Kent, DP Recker The American journal of emergency medicine 20 (4), 275-281, 2002 | 88 | 2002 |
| The COX‐2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial PT Leese, DP Recker, JD Kent The Journal of Clinical Pharmacology 43 (5), 504-513, 2003 | 77 | 2003 |
| for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis … FE Silverstein, G Faich, JL Goldstein, LS Simon, T Pincus, A Whelton, ... JAMA 284 (10), 1247-1255, 2000 | 73 | 2000 |